Noxopharm Completes Final Single-Dose Group in Autoimmune Diseases Drug Candidate Trial, Shares Fall 6%

MT Newswires Live

2025/09/08

Noxopharm (ASX:NOX) said the fourth and last single-dose group of SOF-SKN, a drug candidate for autoimmune diseases like cutaneous lupus erythematosus, was completed in the HERACLES trial, according to a Monday Australian bourse filing.

The safety steering committee determined the dose level to be safe and tolerable, with no clinically relevant issues identified.

The study aims to evaluate the safety and tolerability profile of SOF-SKN by testing it at four different concentrations. Each group is scheduled to take around two weeks due to several tests, including electrocardiograms, physical exams, participant questionnaires, and numerous blood tests.

The firm's shares fell 6% in recent trading on Monday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2565757029"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565757029\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565757029?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 13:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565757029","market":"fut","top_or_hot":-1,"title":"Noxopharm Completes Final Single-Dose Group in Autoimmune Diseases Drug Candidate Trial, Shares Fall 6%","media":"MT Newswires Live","content":"<html><body><p> Noxopharm (ASX:NOX) said the fourth and last single-dose group of SOF-SKN, a drug candidate for autoimmune diseases like cutaneous lupus erythematosus, was completed in the HERACLES trial, according to a Monday Australian bourse filing.</p><p>The safety steering committee determined the dose level to be safe and tolerable, with no clinically relevant issues identified.</p><p>The study aims to evaluate the safety and tolerability profile of SOF-SKN by testing it at four different concentrations. Each group is scheduled to take around two weeks due to several tests, including electrocardiograms, physical exams, participant questionnaires, and numerous blood tests.</p><p>The firm's shares fell 6% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Noxopharm Completes Final Single-Dose Group in Autoimmune Diseases Drug Candidate Trial, Shares Fall 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNoxopharm Completes Final Single-Dose Group in Autoimmune Diseases Drug Candidate Trial, Shares Fall 6%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-08 13:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Noxopharm (ASX:NOX) said the fourth and last single-dose group of SOF-SKN, a drug candidate for autoimmune diseases like cutaneous lupus erythematosus, was completed in the HERACLES trial, according to a Monday Australian bourse filing.</p><p>The safety steering committee determined the dose level to be safe and tolerable, with no clinically relevant issues identified.</p><p>The study aims to evaluate the safety and tolerability profile of SOF-SKN by testing it at four different concentrations. Each group is scheduled to take around two weeks due to several tests, including electrocardiograms, physical exams, participant questionnaires, and numerous blood tests.</p><p>The firm's shares fell 6% in recent trading on Monday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2565757029","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565757029","pubTimestamp":1757310418,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Noxopharm  said the fourth and last single-dose group of SOF-SKN, a drug candidate for autoimmune diseases like cutaneous lupus erythematosus, was completed in the HERACLES trial, according to a Monday Australian bourse filing.The safety steering committee determined the dose level to be safe and tolerable, with no clinically relevant issues identified.The study aims to evaluate the safety and tolerability profile of SOF-SKN by testing it at four different concentrations. Each group is scheduled to take around two weeks due to several tests, including electrocardiograms, physical exams, participant questionnaires, and numerous blood tests.The firm's shares fell 6% in recent trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","NOX.AU":"NOXOPHARM LTD","BK7508":"医药生物股","BK7501":"新冠治疗股"},"translate_title":"Noxopharm完成自身免疫性疾病候选药物试验的最后一个单剂量组，股价下跌6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NOX.AU":0.9},"content_text":"Noxopharm (ASX:NOX) said the fourth and last single-dose group of SOF-SKN, a drug candidate for autoimmune diseases like cutaneous lupus erythematosus, was completed in the HERACLES trial, according to a Monday Australian bourse filing.The safety steering committee determined the dose level to be safe and tolerable, with no clinically relevant issues identified.The study aims to evaluate the safety and tolerability profile of SOF-SKN by testing it at four different concentrations. Each group is scheduled to take around two weeks due to several tests, including electrocardiograms, physical exams, participant questionnaires, and numerous blood tests.The firm's shares fell 6% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}